See more : Pilbara Minerals Limited (PILBF) Income Statement Analysis – Financial Results
Complete financial analysis of Laurus Labs Limited (LAURUSLABS.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Laurus Labs Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Volpara Health Technologies Limited (VPAHF) Income Statement Analysis – Financial Results
- OD6 Metals Limited (OD6.AX) Income Statement Analysis – Financial Results
- Hailir Pesticides and Chemicals Group Co.,Ltd. (603639.SS) Income Statement Analysis – Financial Results
- SKF India Limited (SKFINDIA.NS) Income Statement Analysis – Financial Results
- Hygrovest Limited (MMJJF) Income Statement Analysis – Financial Results
Laurus Labs Limited (LAURUSLABS.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lauruslabs.com
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.02B | 60.14B | 48.89B | 47.23B | 27.59B | 22.40B | 19.97B | 18.65B | 17.51B | 13.14B | 11.56B | 7.19B |
| Cost of Revenue | 43.20B | 28.41B | 22.48B | 21.97B | 14.44B | 12.62B | 10.87B | 10.21B | 10.27B | 9.52B | 8.04B | 4.66B |
| Gross Profit | 6.82B | 31.74B | 26.40B | 25.26B | 13.15B | 9.78B | 9.10B | 8.44B | 7.24B | 3.63B | 3.53B | 2.52B |
| Gross Profit Ratio | 13.63% | 52.77% | 54.01% | 53.48% | 47.65% | 43.67% | 45.56% | 45.25% | 41.33% | 27.60% | 30.50% | 35.14% |
| Research & Development | 437.60M | 255.90M | 294.70M | 172.90M | 151.80M | 131.51M | 134.49M | 119.16M | 37.79M | 497.95M | 389.89M | 332.54M |
| General & Administrative | 666.30M | 638.20M | 618.00M | 489.40M | 442.60M | 265.20M | 198.55M | 165.64M | 139.31M | 122.14M | 141.29M | 1.06B |
| Selling & Marketing | 1.34B | 1.16B | 1.02B | 916.50M | 615.30M | 319.60M | 240.88M | 226.48M | 164.86M | 124.61M | 125.44M | 14.77M |
| SG&A | 2.01B | 1.80B | 1.64B | 1.41B | 1.06B | 584.80M | 439.43M | 392.12M | 304.17M | 246.75M | 266.73M | 1.08B |
| Other Expenses | 0.00 | 60.00M | 8.70M | 41.00M | 46.40M | 57.94M | 42.11M | 28.88M | 13.94M | 2.45M | 3.42M | 0.00 |
| Operating Expenses | 3.01B | 18.79B | 14.68B | 11.79B | 9.35B | 7.65B | 6.18B | 5.38B | 4.44B | 2.22B | 1.76B | 1.36B |
| Cost & Expenses | 46.44B | 47.20B | 37.16B | 33.76B | 23.79B | 20.27B | 17.05B | 15.59B | 14.71B | 11.74B | 9.80B | 6.02B |
| Interest Income | 56.10M | 45.60M | 17.20M | 13.10M | 9.70M | 8.88M | 7.62M | 15.05M | 24.34M | 21.69M | 34.89M | 307.54M |
| Interest Expense | 1.80B | 1.23B | 757.60M | 552.80M | 733.90M | 742.30M | 693.73M | 902.14M | 986.95M | 811.95M | 462.21M | 0.00 |
| Depreciation & Amortization | 3.85B | 3.24B | 2.51B | 2.05B | 1.87B | 1.64B | 1.25B | 1.06B | 864.09M | 615.26M | 328.80M | 224.27M |
| EBITDA | 7.93B | 15.76B | 14.27B | 15.73B | 5.59B | 3.61B | 4.36B | 4.38B | 3.67B | 2.24B | 2.14B | 1.45B |
| EBITDA Ratio | 15.85% | 25.87% | 28.85% | 33.07% | 20.12% | 15.85% | 21.62% | 23.09% | 20.34% | 15.80% | 17.80% | 20.12% |
| Operating Income | 3.95B | 13.14B | 11.88B | 13.22B | 3.40B | 1.81B | 2.71B | 2.94B | 2.81B | 1.46B | 1.73B | 1.22B |
| Operating Income Ratio | 7.89% | 21.85% | 24.31% | 27.98% | 12.31% | 8.09% | 13.57% | 15.76% | 16.04% | 11.12% | 14.96% | 16.99% |
| Total Other Income/Expenses | -1.59B | -1.84B | -912.10M | -495.40M | -854.20M | -932.82M | -547.12M | -669.16M | -1.11B | -740.96M | -555.94M | -360.10M |
| Income Before Tax | 2.36B | 11.09B | 10.84B | 13.01B | 2.94B | 1.20B | 2.37B | 2.35B | 1.69B | 665.69M | 1.21B | 860.99M |
| Income Before Tax Ratio | 4.73% | 18.44% | 22.17% | 27.55% | 10.64% | 5.35% | 11.89% | 12.61% | 9.66% | 5.06% | 10.45% | 11.98% |
| Income Tax Expense | 681.50M | 3.12B | 2.51B | 3.17B | 383.40M | 259.88M | 698.06M | 438.64M | 349.03M | -15.51M | 236.38M | 21.20M |
| Net Income | 1.61B | 7.90B | 8.28B | 9.84B | 2.55B | 937.64M | 1.68B | 1.90B | 1.34B | 683.69M | 972.17M | 882.18M |
| Net Income Ratio | 3.21% | 13.14% | 16.93% | 20.82% | 9.25% | 4.19% | 8.39% | 10.20% | 7.64% | 5.20% | 8.41% | 12.28% |
| EPS | 2.98 | 14.69 | 15.42 | 18.36 | 4.79 | 1.77 | 3.17 | 4.16 | 3.32 | 2.21 | 3.18 | 2.17 |
| EPS Diluted | 2.97 | 14.64 | 15.35 | 18.28 | 4.79 | 1.76 | 3.15 | 4.16 | 2.70 | 1.54 | 2.40 | 2.17 |
| Weighted Avg Shares Out | 538.76M | 537.73M | 536.81M | 535.75M | 533.42M | 531.22M | 529.50M | 452.57M | 402.64M | 308.80M | 305.90M | 406.44M |
| Weighted Avg Shares Out (Dil) | 539.67M | 539.60M | 539.17M | 538.12M | 533.45M | 532.59M | 531.73M | 455.22M | 494.81M | 443.37M | 405.74M | 406.41M |
Source: https://incomestatements.info
Category: Stock Reports